Detail akcie Krystal Biotech Rg online

Business Summary: Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Krystal Biotech Inc revenues increased 41% to $282M. Net income increased from $43.7M to $153.4M. Revenues reflect Pharmaceuticals segment increase from $45.3M to $97.8M. Net income benefited from Pharmaceuticals segment income totaling $41.4M vs. loss of $6.7M. Basic Earnings per Share excluding Extraordinary Items increased from $1.52 to $5.31.